Granted Patent
B2
US 12,611,378 · App. 18/012,362 · Granted Apr 28, 2026
Targeted release rifaximin compositions
Inventors:
Jacob Cole (Fairport, NY); Brian R. Rohrs (Fairport, NY); Daniel J. Stein (Rochester, NY); Robert J. Israel (Suffern, NY); Ezra R. Lowe (Bridgewater, NJ)
Assignee:
Bausch Health Ireland Limited
A61K9/0056A61K31/137A61K31/437A61K31/4468A61K31/485A61K45/06A61K47/10A61K47/14A61K47/32A61K47/38A61P7/00A61P7/04
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are GI specific rifaximin release compositions which can be formulated for targeted delivery of rifaximin to one or more portions of the GI tract. Methods of treating diseases and disorders with the disclosed compositions are also provided.
Claims (9)
1 . A rifaximin bead composition comprising a plurality of sugar spheres coated with rifaximin and a combination of hydroxypropyl methylcellulose (HPMC) and polyvinylpyrrolidone (PVP);
wherein:
HPMC is present in an amount of from about 5% to about 15% by weight based on the total weight of rifaximin in the composition or from about 0.1% to about 2.5% by weight based on the total weight of the composition, and
PVP is present in an amount of from about 15% to about 35% by weight based on the total weight of rifaximin in the composition, or from about 0.5% to about 4.0%, or from about 3.0% to about 8.0% by weight based on the total weight of the composition.
2 . The rifaximin bead composition of claim 1 , wherein HPMC is present in an amount of from about 5% to about 15% by weight based on the total weight of rifaximin in the composition.
3 . The rifaximin bead composition of claim 1 , wherein PVP is present in an amount of from about 15% to about 35% by weight based on the total weight of rifaximin in the composition.
4 . The rifaximin bead composition of claim 1 , further comprising a surfactant.
5 . The rifaximin bead composition of claim 1 , wherein the rifaximin is present in an amount of from about 1% to about 30% by weight based on the total weight of the composition.
6 . A method of treating one or more disorders in a subject in need thereof, comprising the step of administering to said subject a therapeutically effective amount of the composition of claim 1 , wherein the one or more disorders are selected from irritable bowel syndrome (IBS), diarrhea, microbe associated diarrhea, infectious diarrhea, Clostridium difficile infections and symptoms, travelers' diarrhea, small intestinal bacterial overgrowth (SIBO), Crohn's disease, sickle-cell disease, diverticular disease, pancreatitis, pancreatic insufficiency, enteritis, colitis, antibiotic associated colitis, hepatic encephalopathy, gastric dyspepsia, cirrhosis, polycystic liver disease, pouchitis, peritonitis, short bowel syndrome, inflammatory bowel disease, rosacea, and H. pylori infection.
Assignments (7)
U.S. PATENT SECURITY AGREEMENT
Recorded Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
RELEASE OF SECURITY INTEREST
Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 30, 2023
From: COLE, JACOB; ROHRS, BRIAN R.; STEIN, DANIEL J.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 063797/0185 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 30, 2023
From: COLE, JACOB; ROHRS, BRIAN R.; STEIN, DANIEL J.; ISRAEL, ROBERT J.; LOWE, EZRA R.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 063797/0236 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT
Recorded Feb 24, 2023
From: BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062853/0695 →
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
Recorded Feb 24, 2023
From: BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062853/0729 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT
Recorded Feb 24, 2023
From: BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 062853/0655 →
Continuity (4)
Provisional Application
63190349
· May 19, 2021
Provisional Application
63107400
· Oct 29, 2020
Provisional Application
63044450
· Jun 26, 2020
References Cited (246)
US 4341785A
· Marchi et al.
· 1982
[cited by applicant]
US 4557866A
· Cannata et al.
· 1985
[cited by applicant]
US 4717569A
· Harrison et al.
· 1988
[cited by applicant]
US 6352720B1
· Martin et al.
· 2002
[cited by applicant]
US 6861053B1
· Lin et al.
· 2005
[cited by applicant]
US 7045620B2
· Viscomi et al.
· 2006
[cited by applicant]
US 7612199B2
· Viscomi et al.
· 2009
[cited by applicant]
US 7902206B2
· Viscomi et al.
· 2011
[cited by applicant]
US 7906542B2
· Viscomi et al.
· 2011
[cited by applicant]
US 7915275B2
· Viscomi et al.
· 2011
[cited by applicant]
US 7928115B2
· Forbes et al.
· 2011
[cited by applicant]
US 8158644B2
· Viscomi et al.
· 2012
[cited by applicant]
US 8158781B2
· Viscomi et al.
· 2012
[cited by applicant]
US 8193196B2
· Viscomi et al.
· 2012
[cited by applicant]
US 8309569B2
· Forbes et al.
· 2012
[cited by applicant]
US 8383151B2
· Kulkarni et al.
· 2013
[cited by examiner]
US 8518949B2
· Viscomi et al.
· 2013
[cited by applicant]
US 8568782B2
· Viscomi et al.
· 2013
[cited by applicant]
US 8617598B2
· Haeberlin et al.
· 2013
[cited by applicant]
US 8741904B2
· Viscomi et al.
· 2014
[cited by applicant]
US 8835452B2
· Viscomi et al.
· 2014
[cited by applicant]
US 8853231B2
· Viscomi et al.
· 2014
[cited by applicant]
US 9271968B2
· Viscomi et al.
· 2016
[cited by applicant]
US 9737610B2
· Selbo et al.
· 2017
[cited by applicant]
US 20040138231A1
· Bateman et al.
· 2004
[cited by applicant]
US 20050101598A1
· Viscomi et al.
· 2005
[cited by applicant]
US 20070141143A1
· Smithey et al.
· 2007
[cited by applicant]
US 20070218138A1
· Bittorf et al.
· 2007
[cited by applicant]
US 20080095754A1
· Burke et al.
· 2008
[cited by applicant]
US 20090011020A1
· Viscomi et al.
· 2009
[cited by applicant]
US 20090011024A1
· Babcock et al.
· 2009
[cited by applicant]
US 20090028940A1
· Jahagirdar et al.
· 2009
[cited by applicant]
US 20090124670A1
· Sakai
· 2009
[cited by applicant]
US 20100174064A1
· Gushurst et al.
· 2010
[cited by applicant]
US 20110118295A1
· Forbes et al.
· 2011
[cited by applicant]
US 20110312973A1
· Liepold et al.
· 2011
[cited by applicant]
US 20120077835A1
· Selbo et al.
· 2012
[cited by applicant]
US 20120214833A1
· Kulkarni et al.
· 2012
[cited by applicant]
US 20150164866A1
· Randall
· 2015
[cited by applicant]
US 20170027975A1
· Frieman et al.
· 2017
[cited by applicant]
US 20170087134A1
· Golden
· 2017
[cited by examiner]
US 20170333562A1
· Selbo et al.
· 2017
[cited by applicant]
US 20180021297A1
· Hauser
· 2018
[cited by applicant]
US 20190224175A1
· Golden et al.
· 2019
[cited by applicant]
US 20200397904A1
· Selbo et al.
· 2020
[cited by applicant]
US 20220040157A1
· Golden et al.
· 2022
[cited by applicant]
US 20220378758A1
· Angel et al.
· 2022
[cited by applicant]
US 20230027192A1
· Bajaj
· 2023
[cited by applicant]
AU 2014202520A1
· 2014
[cited by applicant]
CN 101137350A
· 2008
[cited by applicant]
CN 101502513A
· 2009
[cited by applicant]
CN 102716168A
· 2012
[cited by applicant]
CN 103118666A
· 2013
[cited by applicant]
CN 103263668A
· 2013
[cited by applicant]
CN 103340856A
· 2013
[cited by applicant]
CN 105025717A
· 2015
[cited by applicant]
CN 107281210A
· 2017
[cited by applicant]
CN 110290781A
· 2019
[cited by applicant]
EP 2011486A1
· 2009
[cited by applicant]
EP 2542225A2
· 2013
[cited by applicant]
EP 1996710B1
· 2019
[cited by applicant]
JP 2002537317A
· 2022
[cited by applicant]
KR 20130098300A
· 2013
[cited by applicant]
KR 20130106400A
· 2013
[cited by applicant]
MX 2012004954A
· 2012
[cited by applicant]
NZ 231622A
· 1991
[cited by applicant]
RU 2609833C2
· 2017
[cited by applicant]
WO WO2002051385A1
· 2002
[cited by applicant]
WO 03101445A1
· 2003
[cited by applicant]
WO 2003101445A1
· 2003
[cited by applicant]
WO 200473692A1
· 2004
[cited by applicant]
WO 2005030142A2
· 2005
[cited by applicant]
WO 2005044823A2
· 2005
[cited by applicant]
WO WO2006026500A1
· 2006
[cited by applicant]
WO 2006094662A1
· 2006
[cited by applicant]
WO WO2006094737A2
· 2006
[cited by applicant]
WO 2007117556A2
· 2007
[cited by applicant]
WO WO2009008005A1
· 2009
[cited by applicant]
WO WO2009108730A2
· 2009
[cited by applicant]
WO WO2009118167A1
· 2009
[cited by applicant]
WO 2010044093A1
· 2010
[cited by applicant]
WO WO2010040020A1
· 2010
[cited by applicant]
WO WO2010067072A1
· 2010
[cited by applicant]
WO WO2011051971A2
· 2011
[cited by applicant]
WO WO2011061748A1
· 2011
[cited by applicant]
WO WO2012009387A1
· 2012
[cited by applicant]
WO WO2012009388A1
· 2012
[cited by applicant]
WO 2012035283A1
· 2012
[cited by applicant]
WO 2012103119A1
· 2012
[cited by applicant]
WO 2006112541A1
· 2013
[cited by applicant]
WO 2014006576A1
· 2014
[cited by applicant]
WO 2016014437A1
· 2016
[cited by applicant]
WO WO2016063289A2
· 2016
[cited by applicant]
WO WO2016178652A1
· 2016
[cited by applicant]
WO WO2018064472A1
· 2018
[cited by applicant]
WO WO2018165404A1
· 2018
[cited by examiner]
WO WO2019178652A1
· 2019
[cited by applicant]
WO WO2020047311A1
· 2020
[cited by applicant]
WO WO2020198136A1
· 2020
[cited by applicant]
WO WO2021108360A1
· 2021
[cited by applicant]
U.S. Appl. No. 13/181,481, filed Jul. 12, 2011, 2012/0077835.
[cited by applicant]
U.S. Appl. No. 14/250,293, filed Apr. 10, 2014, U.S. Pat. No. 9,737,610.
[cited by applicant]
U.S. Appl. No. 15/281,543, filed Sep. 30, 2016, 2017/0087134.
[cited by applicant]
U.S. Appl. No. 15/615,121, filed Jun. 6, 2017, 2017/0333562.
[cited by applicant]
U.S. Appl. No. 16/916,421, filed Jun. 30, 2020, 2020/0397904.
[cited by applicant]
U.S. Appl. No. 16/369,509, filed Mar. 29, 2019, U.S. Pat. No. 10,874,647.
[cited by applicant]
U.S. Appl. No. 17/101,609, filed Nov. 23, 2020.
[cited by applicant]
U.S. Appl. No. 17/174,829, filed Feb. 12, 2021, U.S. Pat. No. 11,129,817.
[cited by applicant]
U.S. Appl. No. 17/468,457, filed Sep. 7, 2021, U.S. Pat. No. 11,311,521.
[cited by applicant]
U.S. Appl. No. 17/468,461, filed Sep. 7, 2021, 2022/0040157.
[cited by applicant]
U.S. Appl. No. 17/779,865, filed May 25, 2022, Pending.
[cited by applicant]
U.S. Appl. No. 17/913,844, filed Sep. 23, 2022, Pending.
[cited by applicant]
U.S. Appl. No. 17/913,843, filed Sep. 23, 2022, Pending.
[cited by applicant]
U.S. Appl. No. 17/918,374, filed Oct. 12, 2022, Pending.
[cited by applicant]
Office Action issued in European Patent Application No. 21739302.4, dated Jun. 13, 2024, 11 pages.
[cited by applicant]
Scarpignato et al., “Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers,” Drug Design, Development, and Therapy…
[cited by applicant]
Siepmann et al., “Polymer Blends for Controlled Release Coatings,” Journal of Controlled Release, 2008, 125:1-15.
[cited by applicant]
Office Action issued in Chinese Patent Application No. 202180052294.0, dated Mar. 27, 2024, 30 pages.
[cited by applicant]
Office Action issued in Eurasian Patent Application No. 202390175, dated Sep. 25, 2023, 12 pages.
[cited by applicant]
Omez® DSR Label (LP-003998-061216. Dec. 6, 2016). State Register of Medicines [online] [retrieved Aug. 31, 2023]. Found on <https://grls.rosminzdrav.ru/InstrImg/2016/12/13/1413974/%D0%9B%D0%9F- 003998[2016]_0.pdf>, 27 p…
[cited by applicant]
International Search Report and Written Opinion issued in PCT/EP2021/067583, dated Sep. 29, 2021, 12 pages.
[cited by applicant]
Acosta et al., Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome. Clin Transl Gastroenterol. May 26, 2016;7(5) :e173, 11 pages.
[cited by applicant]
Bacchi et al., Polymorphism-structure relationships of rifamexil, an antibiotic rifamycin derivative. Mol Pharmacol. 1995;47(3):611-623.
[cited by applicant]
Bajaj et al., Investigational Water-soluble Rifaximin Formulation Significantly Shortens Time to Recovery in Hospitalized Patients with Overt Hepatic Encephalopathy (OHE): A Phase 2, Randomized, Double-blind, Placebo-co…
[cited by applicant]
Bajaj et al., Lactulose Withdrawal Can Potentiate Breakthrough Overt Hepatic Encephalopathy in Patients Controlled wtih Rifaximin Plus Lactulose Therapy: A Post Hoc Analysis of a Randomized Controlled Trial. Crohn's and…
[cited by applicant]
Bajaj et al., Oral Rifaximin Soluble Solid Dispersion Immediate-release 40 mg Prevents Development of Cirrhosis-related Complications: a Phase 2, Randomized, Multicenter, Double-blind, Placebo-controlled Trial. Hepatolo…
[cited by applicant]
Bajaj et al., Rifaximin and Lactulose Combination Therapy Versus Lactulose Alone for Prevention of Overt Hepatic Encephalopathy Recurrence: A Pooled Analysis of Two Randomized Trials. Gastroenterology. 2019;156:S560, Ab…
[cited by applicant]
Bajaj, Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther. Jan. 2016;43 Suppl 1:11-26.
[cited by applicant]
Bavin, Polymorphism in process development. Chemistry & Industry. Aug. 2, 19891;16:527-529.
[cited by applicant]
Blandizzi et al., Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers. Drug Des Devel Ther. Dec. 16, 2014;9:1-11.
[cited by applicant]
Boulware, Travel medicine for the extreme traveler. Dis Mon. 2006;52(8):309-325.
[cited by applicant]
Buhler, Polyvinylpyrrolidone Excipients for Pharmaceuticals, Povidone, Crospovidone and Copovidone. Springer, Chapter 2, Section 2.4.3, pp. 83-98, 2005.
[cited by applicant]
Byrn et al., Hydrates and Solvates. Solid-State Chemistry of Drugs, Second Edition. SSCI, Inc., Chapter 11, pp. 233-247, (1999).
[cited by applicant]
Byrn et al., Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm Res. 1995;12(7):945-954.
[cited by applicant]
Castelli et al., Epidemiology of travelers' diarrhea. J Travel Med. 2001;8(Suppl 2):S26-S30.
[cited by applicant]
Cheng et al., Update on Traveler's Diarrhea. Curr Infect Dis Rep. 2002;4(1):70-77.
[cited by applicant]
ClinicalTrials.gov, Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea. Identifier: NCT00098384, 6 pages, May 9, 2006.
[cited by applicant]
ClinicalTrials.gov, Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea. Identifier: NCT00292344, 6 pages, Apr. 20, 2009.
[cited by applicant]
Crum et al., New issues in infectious diarrhea. Rev Gastroenterol Disord. 2005;5 Suppl 3:S16-S25.
[cited by applicant]
Datta et al., Crystal structures of drugs: advances in determination, prediction and engineering. Nat Rev Drug Discov. 2004;3(1):42-57.
[cited by applicant]
Dupont et al., A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142(10):805-812.
[cited by applicant]
Dupont et al., Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33(11):1807-1815.
[cited by applicant]
Dupont et al., Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol. 2007;5(4):451-456.
[cited by applicant]
Dupont, Treatment of travelers' diarrhea. J Travel Med. 2001;8(Suppl 2):S31-S33.
[cited by applicant]
Dutta et al., Effects of rifaximin on circulating aged neutrophils in sickle cell disease. Am J Hematol. Jun. 2019;94(6):E175-E176.
[cited by applicant]
Dutta et al., Rifaximin on intestinally-related pathologic changes in sickle cell disease. Am J Hematol. Apr. 2020;95(4):E83-E86.
[cited by applicant]
Emea, ICH Topic Q 6 A, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. European Medicines Agency, CPMP/ICH/367/96. 32 pages, May 2000.
[cited by applicant]
Ericsson, Rifaximin: a new approach to the treatment of travelers' diarrhea. Introduction. J Travel Med. 2001;8(Suppl 2):S25-S26.
[cited by applicant]
Evonik Industries, EUDRAGIT® Acrylic Drug Delivery Polymers. Retrieved online at: http://eudragit.evonik.com/product/eudragit/en/products-services/eudragit-products/pages/default.aspx>> published on Apr. 23, 2010 as per…
[cited by applicant]
FDA, Guideline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances. Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human S…
[cited by applicant]
Fiorucci et al., Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion. 2002;66(4):…
[cited by applicant]
Gbinigie et al., Should azithromycin be used to treat COVID-19? A rapid review. BJGP Open. Jun. 23, 2020;4(2):1-8.
[cited by applicant]
Gerard et al., Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther. 2005;3(2):201-211.
[cited by applicant]
Ghoshal et al., Models for prediction of mortality from cirrhosis with special reference to artificial neural network: a critical review. Hepatol Int. 2008;2(1):31-38.
[cited by applicant]
Gillis et al., Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995;49(3):467-484.
[cited by applicant]
Gionchetti et al., Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci. 1999;44(6):1220-1221.
[cited by applicant]
Guillory, Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids. Materials Science. Chapter 5, pp. 183-226, (1999).
[cited by applicant]
Hancock et al., Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. Jan. 1997;86(1):1-12.
[cited by applicant]
Huang et al., Rifaximin—a novel antimicrobial for enteric infections. J Infect. 2005;50(2):97-106.
[cited by applicant]
Infante et al., Enteroaggregative
[cited by applicant]
Jozwiakowski, Alteration of the Solid State of the Drug Substance: Polymorphs, Solvates, and Amorphous Forms. Water-Insoluble Drug Formulation. Ron Liu (Ed.), Taylor & Francis Group. Chapter 15, pp. 525-568, (2000).
[cited by applicant]
Kakiyama et al., Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. May 2013;58(5):949-55.
[cited by applicant]
Kalambokis et al., Rifaximin for the prevention of spontaneous bacterial peritonitis. World J Gastroenterol. Apr. 14, 2012;18(14):1700-1702.
[cited by applicant]
Kalhor et al., Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches. J Biomol Struct Dyn. Feb. 2022;40(3):1299-1315.
[cited by applicant]
Kalil et al., Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. May 19, 2020;323(19):1897-1898.
[cited by applicant]
Kallai et al., Evaluation of drug release from coated pellets based on isomalt, sugar, and microcrystalline cellulose inert cores. AAPS PharmSciTech. Mar. 2010;11(1):383-91.
[cited by applicant]
Khankari et al., Pharmaceutical hydrates. Thermochimica Acta. 1995;248:61-79.
[cited by applicant]
Koo et al., Current and future developments in travelers' diarrhea therapy. Expert Rev Anti Infect Ther. 2006;4(3):417-427.
[cited by applicant]
Koo et al., The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea. Ther Clin Risk Manag. 2009;5:841-848.
[cited by applicant]
Leuner et al., Improve Drug Solubility for Oral Delivery using Solid Dispersions. European Journal of Pharmaceutics and Biopharmaceutics. 2000;50:47-60.
[cited by applicant]
Lim et al., Clinicopathologic consequences following discontinuation of rifaximin in patients with sickle cell disease. Am J Hematol. Jun. 2020;95(6):E151-E153.
[cited by applicant]
Lim et al., Rifaximin for sickle cell disease. Am J Hematol. Dec. 2019;94(12):E325-E328.
[cited by applicant]
Malamud et al., Treatment of gastrointestinal infections. Curr Opin Gastroenterol. 2000;16(1):51-55.
[cited by applicant]
Martins, et al., Microstructured Ternary Solid Dispersions to Improve Carbamazepine Solubility. Powder Technology. Jan. 2012;215-216:156-165.
[cited by applicant]
Mas et al., Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38(1):51-58.
[cited by applicant]
Miglioli et al., Effects of daily oral administration of rifaximin and neomycin on faecal aerobic flora in rats. Pharmacol Res. 2001;44(5):373-375.
[cited by applicant]
Neff et al., Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc. 2006;38(10):3552-3555.
[cited by applicant]
New York Medical College. Rifaximin to Modify the Disease Course in Sickle Cell Disease. NCT03719729. Oct. 25, 2018, <https://clinicaltrials.gov/ct2/show/study/NCT03719729>.
[cited by applicant]
Newman et al., Form Selection of Pharmaceutical Compounds. Handbook of Pharmaceutical Analysis. Lena Ohannesian (Ed.), Marcel Dekker, Inc., New York. Chapter 1, 61 pages, (2002).
[cited by applicant]
Nguyenla et al., Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells. bioRxiv, retrieved onilne at: https://www.biorxiv.org/content/10.1101/2020.09.18.302398v1.full.pdf. 3…
[cited by applicant]
Paik et al., Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J. 2005;46(3):399-407.
[cited by applicant]
Pakyz, Rifaximin: a new treatment for travelers' diarrhea. Ann Pharmacother. 2005;39(2):284-289.
[cited by applicant]
Pawlowski et al., Diagnosis and treatment of acute or persistent diarrhea. Gastroenterology. 2009;136(6):1874-1886.
[cited by applicant]
Pelizza et al., Polymorphism of rifampicin. Farmaco Sci. 1977;32(7):471-481.
[cited by applicant]
Pigott, Foodborne illness. Emerg Med Clin North Am. 2008;26(2):475-497.
[cited by applicant]
Preidis et al., Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology. 2009;136(6):2015-2031.
[cited by applicant]
Sahraei et al., Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. Apr. 2020;55(4):105945.
[cited by applicant]
Sanyal et al., Impact of Baseline Chronic Liver Disease Characteristics on the Efficacy of Oral Rifaximin Soluble Solid Dispersion Tablets for the Prevention of Further Decompensationor All-Cause Mortality in Patients W…
[cited by applicant]
Scarpignato et al., Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. Chemotherapy. 1995;41 Suppl 1:48-81.
[cited by applicant]
Scarpignato et al., Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005;51 Suppl 1:36-66.
[cited by applicant]
Solanki et al., Multiple Unit Dosage Forms: a Review. Pharmtechmedica. 2012;1(1):11-21.
[cited by applicant]
Steffen et al., Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol. 2003;98(5):1073-1078.
[cited by applicant]
Steffen, Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea. J Travel Med. 2001;8(Suppl 2):S34-S39.
[cited by applicant]
Su et al., Utility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology. Gastroenterol Hepatol (N Y). 2006;2(3):186-197.
[cited by applicant]
Taylor et al., A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg. 2006;74(6):1060-1066.
[cited by applicant]
Taylor et al., Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother. 2008;52(3):1179-1181.
[cited by applicant]
Trinh et al., Diarrheal diseases in the elderly. Clin Geriatr Med. 2007;23(4):833-856.
[cited by applicant]
Van Den Mooter, Solid Dispersions as a Formulation Strategy for Poorly Soluble Compounds. 20th Annual Symposium of the Finish Society of Physical Pharmacy; Vithi, Finland; Katholieke Universiteit Leuven; 37 pages; Jan. …
[cited by applicant]
Vasconcelos et al., Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. Dec. 2007;12(23-24):1068-75.
[cited by applicant]
Vijayasekar, The Impact of COVID-19 Pandemic on Gastroenterology (GI) Outpatient Care: Pros and Cons of Telehealthcare. AMerican College of Gastroenterology. Retrieved online at: https://acgcasereports.gi.org/media/pres…
[cited by applicant]
Vippagunta et al., Crystalline solids. Adv Drug Deliv Rev. 2001;48(1):3-26.
[cited by applicant]
Viscomi et al., Crystal forms of rifaximin and their effect on pharmaceutical properties. CrystEngComm. 2008;10:1074-1081.
[cited by applicant]
Visser et al., Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240. Eur J Pharm Biopharm. Feb. 2010;74(2):233-8.
[cited by applicant]
Vlachogiannakos et al., Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. Mar. 2013;28(3):450-5.
[cited by applicant]
Wagner et al., Travellers' diarrhoea—pros and cons of different prophylactic measures. Wien Klin Wochenschr. Oct. 2009;121 Suppl 3:13-8.
[cited by applicant]
Williams et al., Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. Rev Gastroenterol Disord. 2005;5 Suppl 1:S10-S18.
[cited by applicant]
Xifaxan (rifaximin) Tablets, NDA 21-361/S-006. www.salix.com, 16 pages, (2006).
[cited by applicant]
Xifaxan (rifaximin) Tablets, Revised Xifaxan Label. www.salix.com, 13 pages, May 21, 2004.
[cited by applicant]
Declaration Under 37 C.F. R. Sec. 1.132 for U.S. Pat. No. 10,728,090. Polymorph forms of rifaximin, processes for their production and use thereof in medicinal preparations. Viscomi. 12 pages, Jan. 10, 2006.
[cited by applicant]
Decision to Grant issued in Russian Patent Application No. 2022110800, dated Jul. 1, 2024, 25 pages.
[cited by applicant]
Decision on Rejection issued in Chinese Patent Application No. 202080067056.2, dated Sep. 9, 2024, 21 pages.
[cited by applicant]
Office Action issued in Chinese Patent Application No. 202080067056.2, dated Apr. 26, 2024, 21 pages.
[cited by applicant]
Office Action issued in European Patent Application No. 19163419.5, dated Mar. 13, 2024, 6 pages.
[cited by applicant]
Office Action issued in European Patent Application No. 20785690.7, dated Apr. 17, 2024, 7 pages.
[cited by applicant]
Office Action issued in U.S. Appl. No. 18/628,353, dated Aug. 22, 2024, 14 pages.
[cited by applicant]
Office Action issued in U.S. Appl. No. 18/628,366, dated Sep. 17, 2024, 16 pages.
[cited by applicant]
Office Action issued in Brazilian Patent Application No. 112022003500-4, dated Aug. 27, 2024, 5 pages.
[cited by applicant]
Sharara et al., A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence, Am J Gastroenterol, 101:326-333, 2006.
[cited by applicant]
Marchina et al., Infectious diarrhea in the aged: controlled clinical trial of Rifaximin, Chemioterapia, 7(5):336-40, 1988.
[cited by applicant]
Kornbluth Asher: “Efficacy and Safety of Open Label Rifaximin in the Treatment of Mild-Moderate Crohn's Disease (CD) Refractory to Multiple Medical Therapies”, American College of Gastroenterology, vol. 111, Sep. 1, 200…
[cited by applicant]
Kornbluth Asher et al: “Efficacy and Safety of Rifaximin in the Treatment of Mild-Moderate Crohn's Disease: Results of An Ope⋅⋅Label Pilot Study”, Gastroenterology, vol. 128, No. 4 Suppl 2, Apr. 1, 2005, pp. A-579, XP93…
[cited by applicant]
Prantera et al: “Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo. controlled trial with rifaximin”, Alimentary Pharmacology & Therapeutics, Blackwell Scientific Publi…
[cited by applicant]
Lu Bin, People's Health Publishing House, New Techniques and New Dosage Forms of Drugs, 2nd version in Jul. 2005, date of publication: May 31, 2005, pp. 51-53.
[cited by applicant]
Office Action issued in Japanese Patent Application No. 2022-518665, mailed Oct. 1, 2024, 9 pages.
[cited by applicant]
Arya, et al., “Rifaximin the promising anti-microbial for enteric infections”, Journal of Infection, Academic Press, Loondon, GB, (Oct. 1, 2005), vol. 51, No. 3, p. 262.
[cited by applicant]
Office Action issued in Mexican Patent Application No. MX/a/2022/003481, dated Oct. 18, 2024, 12 pages.
[cited by applicant]
Office Action issued in corresponding Chinese Application No. 202180052294.0, dated Nov. 6, 2024, 18 pages.
[cited by applicant]
Decision on Rejection issued in Chinese Patent Application No. 202180052294.0, dated Apr. 7, 2025, 31 pages.
[cited by applicant]
Office Action issued in U.S. Appl. No. 18/012,362, dated Feb. 12, 2025, 12 pages.
[cited by applicant]
Office Action issued in Mexican Patent Application No. MX/a/2022/003481, dated Apr. 22, 2025, 12 pages.
[cited by applicant]
Office Action issued in U.S. Appl. No. 17/779,865, dated Mar. 13, 2025, 25 pages.
[cited by applicant]
Hughes, J.P., Rees, S., Kalindjian, S.B., Philpott, K.L., Principles of early drug discovery, British Journal of Pharmacology, 162, p. 1239-1249 (Year: 2011).
[cited by applicant]
Li, T. and Chiang, J.Y.L., Bile Acid Signaling in Metabolic Disease and Drug Therapy, Pharmacological Reviews, 66, p. 948-983 (Year: 2014).
[cited by applicant]
Calanni, F., Renzulli, C., Barbanti, M, and Viscomi, G.C., Rifaximin: beyond the traditional antibiotic acitivty, The Journal of Antibiotics, 67, p. 667-670 (Year: 2014).
[cited by applicant]
Shayto, R. H, Mrad, R.A., and Sharara, A.I., Use of rifaximin in gastrointestinal and liver diseases, World Journal of Gastroenterology, 22, p. 6638-6651 (Year: 2016).
[cited by applicant]
Cosmetic Ingredient Information Online “PEG-60 Hydrogenated Castor Oil,” https://cosmetic-ingredients.org/surfactants-emulsifying-agents/2066/.
[cited by applicant]
Office Action issued in Japanese Patent Application No. 2022-518665, dated Apr. 1, 2025, 9 pages.
[cited by applicant]
Office Action issued in Eurasian Patent Application No. 202390175, dated May 22, 2025, 25 pages.
[cited by applicant]
Office Action issued in Japanese Patent Application No. 2022-580309, mailed Jul. 15, 2025, 7 pages.
[cited by applicant]
Office Action issued in Canadian Patent Application. No. 3,151,010, dated Sep. 5, 2025, 3 pages.
[cited by applicant]
Office Action issued in Australian Patent Application No. 2020355603, dated Aug. 22, 2025, 4 pages.
[cited by applicant]
Office Action issued in U.S. Appl. No. 17/779,865, dated Sep. 19, 2025, 12 pages.
[cited by applicant]